Global Consensus Guidelines for MASLD and MASH

Global Consensus Guidelines for MASLD and MASH

The Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), represent a landmark effort by an international multidisciplinary panel of 50+ experts from hepatology, endocrinology, and primary care. Developed via a two-round modified Delphi process (87% agreement threshold) and systematic literature review (up to May 2024), these guidelines update prior NAFLD/NASH frameworks to align with the 2023 nomenclature shift, focusing on cardiometabolic drivers to enhance diagnostic precision and therapeutic equity.

FDA Approves Breakthrough Twice-Yearly HIV Prevention Shot Yeztugo

FDA Approves Breakthrough Twice-Yearly HIV Prevention Shot Yeztugo

The World Health Organization (WHO) has published its first global guideline on managing sickle cell disease (SCD) during pregnancy—marking a critical step in addressing the serious health risks this condition poses for both mothers and babies. SCD, a group of inherited blood disorders, causes red blood cells to become abnormally shaped, leading to complications such as severe anemia, pain crises, infections, and life-threatening events like strokes and organ failure.

Dapagliflozin-Induced Immune Hemolytic Anemia: A Case Report

Dapagliflozin-Induced Immune Hemolytic Anemia: A Case Report

This case report details an extremely rare disease called drug-induced immune hemolytic anemia (DIIHA) that developed in a 52-year-old man once he started using the drug dapagliflozin (Farxiga), a drug often prescribed for diabetes. The report speculates that this could be the first to link this particular drug to this unusual disorder. DIIHA is a dangerous side effect wherein the immune system abnormally reacts against and destroys red blood cells upon exposure to a drug. While extremely uncommon, affecting 1-2 people per million individuals per year, it is life-threatening unless treated.